|
1
|
Negoita S, Feuer EJ, Mariotto A, Cronin
KA, Petkov VI, Hussey SK, Benard V, Henley SJ, Anderson RN, Fedewa
S, et al: Annual report to the nation on the status of cancer, part
II: Recent changes in prostate cancer trends and disease
characteristics. Cancer. 124:2801–2814. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ansari D, Tingstedt B, Andersson B,
Holmquist F, Sturesson C, Williamsson C, Sasor A, Borg D, Bauden M
and Andersson R: Pancreatic cancer: Yesterday, today and tomorrow.
Future Oncol. 12:1929–1946. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ryan DP, Hong TS and Bardeesy N:
Pancreatic adenocarcinoma. N Engl J Med. 371:2140–2141. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hidalgo M: Pancreatic cancer. N Engl J
Med. 362:1605–1617. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yáñez-Mó M, Barreiro O, Gordon-Alonso M,
Sala-Valdés M and Sánchez-Madrid F: Tetraspanin-enriched
microdomains: A functional unit in cell plasma membranes. Trends
Cell Biol. 19:434–446. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Anderson KR, Singer RA, Balderes DA,
Hernandez-Lagunas L, Johnson CW, Artinger KB and Sussel L: The L6
domain tetraspanin Tm4sf4 regulates endocrine pancreas
differentiation and directed cell migration. Development.
138:3213–3224. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Richardson MM, Jennings LK and Zhang XA:
Tetraspanins and tumor progression. Clin Exp Metastasis.
28:261–270. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Müller-Pillasch F, Wallrapp C, Lacher U,
Friess H, Büchler M, Adler G and Gress TM: Identification of a new
tumour-associated antigen TM4SF5 and its expression in human
cancer. Gene. 208:25–30. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lee SA, Lee SY, Cho IH, Oh MA, Kang ES,
Kim YB, Seo WD, Choi S, Nam JO, Tamamori-Adachi M, et al:
Tetraspanin TM4SF5 mediates loss of contact inhibition through
epithelial-mesenchymal transition in human hepatocarcinoma. J Clin
Invest. 118:1354–1366. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kwon S, Choi KC, Kim YE, Ha YW, Kim D,
Park BK, Wu G, Kim DS, Lee Y and Kwon HJ: Monoclonal antibody
targeting of the cell surface molecule TM4SF5 inhibits the growth
of hepatocellular carcinoma. Cancer Res. 74:3844–3856. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lee JW: TM4SF5-mediated protein-protein
networks and tumorigenic roles. BMB Rep. 47:483–487. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim H, Kang M, Lee SA, Kwak TK, Jung O,
Lee HJ, Kim SH and Lee JW: TM4SF5 accelerates G1/S phase
progression via cytosolic p27Kip1 expression and RhoA activity.
Biochim Biophys Acta. 1803:975–982. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Choi S, Lee SA, Kwak TK, Kim HJ, Lee MJ,
Ye SK, Kim SH, Kim S and Lee JW: Cooperation between integrin
alpha5 and tetraspan TM4SF5 regulates VEGF-mediated angiogenic
activity. Blood. 113:1845–1855. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wu G, Kim D, Park BK, Park S, Ha JH, Kim
TH, Gautam A, Kim JN, Lee SI, Park HB, et al: Anti-metastatic
effect of the TM4SF5-specific peptide vaccine and humanized
monoclonal antibody on colon cancer in a mouse lung metastasis
model. Oncotarget. 7:79170–79186. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim YE, Kwon S, Wu G, Kim D, Park BK, Park
JA, Choi KC, Kim DS, Kwon HJ and Lee Y: Therapeutic effect of a
TM4SF5-specific monoclonal antibody against colon cancer in a mouse
model. Oncotarget. 5:8402–8415. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Köhler G and Milstein C: Continuous
cultures of fused cells secreting antibody of predefined
specificity. Nature. 256:495–497. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Winter G and Milstein C: Man-made
antibodies. Nature. 349:293–299. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chames P, Van Regenmortel M, Weiss E and
Baty D: Therapeutic antibodies: Successes, limitations and hopes
for the future. Br J Pharmacol. 157:220–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Weiner LM, Murray JC and Shuptrine CW:
Antibody-based immunotherapy of cancer. Cell. 148:1081–1084. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kwon S, Kim D, Park BK, Cho S, Kim KD, Kim
YE, Park CS, Ahn HJ, Seo JN, Choi KC, et al: Prevention and therapy
of hepatocellular carcinoma by vaccination with TM4SF5
epitope-CpG-DNA-liposome complex without carriers. PLoS One.
7:e331212012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kwon S, Kim YE, Kim D, Park BK, Wu G, Kim
TH, Choi SH, Kim DS, Kwon HJ and Lee Y: Prophylactic effect of a
peptide vaccine targeting TM4SF5 against colon cancer in a mouse
model. Biochem Biophys Res Commun. 435:134–139. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Park S, Kim D, Wu G, Jung H, Park JA, Kwon
HJ and Lee Y: A peptide-CpG-DNA-liposome complex vaccine targeting
TM4SF5 suppresses growth of pancreatic cancer in a mouse allograft
model. OncoTargets Ther. 11:8655–8672. 2018. View Article : Google Scholar
|
|
23
|
Park BK, Park JY, Kim TH, Kim D, Wu G,
Gautam A, Maharjan S, Lee SI, Lee Y, Kwon HJ and Choi KC:
Production of an anti-TM4SF5 monoclonal antibody and its
application in the detection of TM4SF5 as a possible marker of a
poor prognosis in colorectal cancer. Int J Oncol. 53:275–285.
2018.PubMed/NCBI
|
|
24
|
Detchokul S, Williams ED, Parker MW and
Frauman AG: Tetraspanins as regulators of the tumour
microenvironment: Implications for metastasis and therapeutic
strategies. Br J Pharmacol. 171:5462–5490. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vences-Catalán F, Rajapaksa R, Srivastava
MK, Marabelle A, Kuo CC, Levy R and Levy S: Tetraspanin CD81
promotes tumor growth and metastasis by modulating the functions of
T regulatory and myeloid-derived suppressor cells. Cancer Res.
75:4517–4526. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zijlstra A, Lewis J, Degryse B, Stuhlmann
H and Quigley JP: The inhibition of tumor cell intravasation and
subsequent metastasis via regulation of in vivo tumor cell motility
by the tetraspanin CD151. Cancer Cell. 13:221–234. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu CY, Lin HH, Tang MJ and Wang YK:
Vimentin contributes to epithelial-mesenchymal transition cancer
cell mechanics by mediating cytoskeletal organization and focal
adhesion maturation. Oncotarget. 6:15966–15983. 2015.PubMed/NCBI
|
|
28
|
Tian X, Liu Z, Niu B, Zhang J, Tan TK, Lee
SR, Zhao Y, Harris DC and Zheng G: E-cadherin/β-catenin complex and
the epithelial barrier. J Biomed Biotechnol. 2011:5673052011.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ahn HM, Ryu J, Song JM, Lee Y, Kim HJ, Ko
D, Choi I, Kim SJ, Lee JW and Kim S: Anti-cancer activity of novel
TM4SF5-targeting antibodies through TM4SF5 neutralization and
immune cell-mediated cytotoxicity. Theranostics. 7:594–613. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Diamantis N and Banerji U: Antibody-drug
conjugates-an emerging class of cancer treatment. Br J Cancer.
114:362–367. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Perez HL, Cardarelli PM, Deshpande S,
Gangwar S, Schroeder GM, Vite GD and Borzilleri RM: Antibody-drug
conjugates: Current status and future directions. Drug Discov
Today. 19:869–881. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Berezhnaya NM, Belova OB, Vinnichuk YD and
Tarutinov VI: Expression of E-cadherin in drug resistant human
breast cancer cells and their sensitivity to lymphokine-activated
lymphocytes action. Exp Oncol. 31:242–245. 2009.PubMed/NCBI
|
|
33
|
Chen X, Wang Y, Xia H, Wang Q, Jiang X,
Lin Z, Ma Y, Yang Y and Hu M: Loss of E-cadherin promotes the
growth, invasion and drug resistance of colorectal cancer cells and
is associated with liver metastasis. Mol Biol Rep. 39:6707–6714.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lazarova DL and Bordonaro M: Vimentin,
colon cancer progression and resistance to butyrate and other
HDACis. J Cell Mol Med. 20:989–993. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Arumugam T, Ramachandran V, Fournier KF,
Wang H, Marquis L, Abbruzzese JL, Gallick GE, Logsdon CD, McConkey
DJ and Choi W: Epithelial to mesenchymal transition contributes to
drug resistance in pancreatic cancer. Cancer Res. 69:5820–5828.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li Y, VandenBoom TG II, Kong D, Wang Z,
Ali S, Philip PA and Sarkar FH: Up-regulation of miR-200 and let-7
by natural agents leads to the reversal of
epithelial-to-mesenchymal transition in gemcitabine-resistant
pancreatic cancer cells. Cancer Res. 69:6704–6712. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xie CG, Wei SM, Chen JM, Xu XF, Cai JT,
Chen QY and Jia LT: Down-regulation of GEP100 causes increase in
E-cadherin levels and inhibits pancreatic cancer cell invasion.
PLoS One. 7:e378542012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gradiz R, Silva HC, Carvalho L, Botelho MF
and Mota-Pinto A: MIA PaCa-2 and PANC-1-pancreas ductal
adenocarcinoma cell lines with neuroendocrine differentiation and
somatostatin receptors. Sci Rep. 6:216482016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Teixidó C, Marés R, Aracil M, Ramón y
Cajal S and Hernández-Losa J: Epithelial-mesenchymal transition
markers and HER3 expression are predictors of elisidepsin treatment
response in breast and pancreatic cancer cell lines. PLoS One.
8:e536452013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Nishino H, Takano S, Yoshitomi H, Suzuki
K, Kagawa S, Shimazaki R, Shimizu H, Furukawa K, Miyazaki M and
Ohtsuka M: Grainyhead-like 2 (GRHL2) regulates epithelial
plasticity in pancreatic cancer progression. Cancer Med.
6:2686–2696. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lafitte M, Moranvillier I, Garcia S,
Peuchant E, Iovanna J, Rousseau B, Dubus P, Guyonnet-Dupérat V,
Belleannée G, Ramos J, et al: FGFR3 has tumor suppressor properties
in cells with epithelial phenotype. Mol Cancer. 12:832013.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Burris HA III, Moore MJ, Andersen J, Green
MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo
AM, Tarassoff P, et al: Improvements in survival and clinical
benefit with gemcitabine as first-line therapy for patients with
advanced pancreas cancer: A randomized trial. J Clin Oncol.
15:2403–2413. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Teague A, Lim KH and Wang-Gillam A:
Advanced pancreatic adenocarcinoma: A review of current treatment
strategies and developing therapies. Ther Adv Med Oncol. 7:68–84.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Huang ZQ and Buchsbaum DJ: Monoclonal
antibodies in the treatment of pancreatic cancer. Immunotherapy.
1:223–229. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chames P, Kerfelec B and Baty D:
Therapeutic antibodies for the treatment of pancreatic cancer.
ScientificWorldJournal. 10:1107–1120. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Luedke E, Jaime-Ramirez AC, Bhave N and
Carson WE III: Monoclonal antibody therapy of pancreatic cancer
with cetuximab: Potential for immune modulation. J Immunother.
35:367–373. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Harder J, Ihorst G, Heinemann V, Hofheinz
R, Moehler M, Buechler P, Kloeppel G, Röcken C, Bitzer M, Boeck S,
et al: Multicentre phase II trial of trastuzumab and capecitabine
in patients with HER2 overexpressing metastatic pancreatic cancer.
Br J Cancer. 106:1033–1038. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Forero-Torres A, Infante JR, Waterhouse D,
Wong L, Vickers S, Arrowsmith E, He AR, Hart L, Trent D, Wade J, et
al: Phase 2, multicenter, open-label study of tigatuzumab
(CS-1008), a humanized monoclonal antibody targeting death receptor
5, in combination with gemcitabine in chemotherapy-naive patients
with unresectable or metastatic pancreatic cancer. Cancer Med.
2:925–932. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Philip PA, Goldman B, Ramanathan RK, Lenz
HJ, Lowy AM, Whitehead RP, Wakatsuki T, Iqbal S, Gaur R, Benedetti
JK and Blanke CD: Dual blockade of epidermal growth factor receptor
and insulin-like growth factor receptor-1 signaling in metastatic
pancreatic cancer: Phase Ib and randomized phase II trial of
gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus
erlotinib (SWOG S0727). Cancer. 120:2980–2985. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Van Cutsem E, Vervenne WL, Bennouna J,
Humblet Y, Gill S, Van Laethem JL, Verslype C, Scheithauer W, Shang
A, Cosaert J and Moore MJ: Phase III trial of bevacizumab in
combination with gemcitabine and erlotinib in patients with
metastatic pancreatic cancer. J Clin Oncol. 27:2231–2237. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Karanikas M, Esempidis A, Chasan ZT,
Deftereou T, Antonopoulou M, Bozali F, Amarantidis K and Man YG:
Pancreatic cancer from molecular pathways to treatment opinion. J
Cancer. 7:1328–1339. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Slingluff CL Jr: The present and future of
peptide vaccines for cancer: Single or multiple, long or short,
alone or in combination? Cancer J. 17:343–350. 2011. View Article : Google Scholar : PubMed/NCBI
|
